Allogeneic hematopoietic cell transplantation (HCT) is increasingly used for patients with NHL. PET has become a standard for lymphoma evaluation and a valuable prognostic tool to risk-stratify treatments. The role of PET in the allogeneic HCT setting is controversial.
ALLOGENEIC STEM CELL TRANSPLANTATION IN 59 PATIENTS WITH
ADULT T-CELL LEUKEMIA/LYMPHOMA (ATLL) -A SINGLE CENTER'S 13 YEARS EXPERIENCE Nakano, N., Takatsuka, Y., Takeuchi, S., Tokunaga, M., Kubota, A., Tokunaga, M., Itoyama, T., Makino, T., Utsunomiya, A. Imamura Bun-in Hospital, Kagoshima, Japan There were 59 (33 male, 26 female) ATLL patients who have consecutively undergone allo-SCT between June 1998 and March 2011 at Imamura Bun-in Hospital. Median age was 50 (range: 32-65) years. Fifty patients were considered 0-1 of ECOG performance status (PS) and rest of 9 were $2 at the time of SCT. Fifty-three patients out of 59 were diagnosed as acute type ATLL, 5 lymphoma type, and one chronic type with poor prognostic factors at the time of transplantation, respectively. Stem cell sources were 36 BM (9 related donors, 27 unrelated donors), 19 PB and 4 CB, respectively. Thirty-five patients received myeloablative conditioning (MAC) regimens and 24 reduced intensity conditioning (RIC) regimens. Forty-seven pa-tients out of 59 were used busulfan based non-TBI regimens. Sixteen patients were in CR at SCT, and 43 non-CR (9 PR, 16 SD, and 18 PD), respectively. Cumulative incidence of ANC recovery ($500/ ml) was 98.2% after SCT. Probabilities of grade I to IV, II to IV acute GVHD and chronic GVHD were 71%, 44%, and 31%, respectively. Interestingly, the incidence of CMV viremia, defined CMV-related external matrix protein pp65-antigenemia positive in blood, after SCT was extremely high (94.4%) in ATLL patient status post SCT compared with reported other diseases. Overall survival (OS) and disease free survival (DFS) at 2 years after SCT were 44.5% and 32.5%, respectively. Notably, 2-yrs and 5-yrs OS in CR patients were 72.7% and 48.5%, respectively. Cumulative incidence of relapse at day100 and 1 year after SCT were 33.2% and 49.2% respectively. Also cumulative incidence of non-relapse mortality (NRM) at day100 after SCT was 20.4%. In univariate analysis, significant factors contributed to OS were CR status and 0-1 of PS at SCT, incidence of acute and chronic GVHD, HLA matched donor, and non-TBI regimens. CR status, 0-1 of PS at SCT, incidence of chronic GVHD, BM, and HLA matched donor were significant factors contributed to favorable outcome about DFS. MAC regimens didn't show favorable significance contributed to OS and DFS, but reduce the incidence of early relapse compared with RIC regimen. In multivariate analysis, incidence of chronic GVHD significantly contributed to favorable outcome about OS and 0-1 of PS, incidence of chronic GVHD and CR status contributed to favorable outcome about DFS. In conclusion, allo-SCT can be feasible treatment for ATLL and graft-versus-ATLL effect possibly exist given that chronic GVHD was shown favorable survival factors. We are performing a clinical trial using T-cell depleted allogeneic HSCT (TCD HSCT) from HLA compatible donors for patients (pts) with relapsed multiple myeloma (MM) and high-risk cytogenetics. Pts receive busulfan, melphalan, fludarabine and rabbit ATG followed by allo TCD HSCT. T-cell depletion is performed by positive CD34 selection achieving \ 10 4 CD3+/kg for all grafts. Pts are eligible to receive low doses of donor lymphocyte infusions (DLI) (5x10e 5 -1x10e 6 CD3+/kg) no earlier than 5mos post TCD HSCT.
We evaluated the significance of WT1-specific cellular immune responses following TCD HSCT and DLI in these pts. WT1-specific T-cell frequencies were determined in peripheral blood and bone marrow specimens by staining for intracellular IFN-g production in response to WT1 peptides, and/or by tetramer analysis, where available.
Of 17 pts evaluated, all pts exhibited low frequencies of WT1-specific T-cell responses pre TCD HSCT. Ten of these pts received DLI post TCD HSCT. All 10 pts developed increased WT1-specific T cell responses post DLI. These increments in WT1-specific T-cell frequencies were associated with reduction in specific myeloma markers. Four pts with increasing M protein post TCD HSCT achieved durable complete remissions post DLI in the abscence of GvHD and are currently 18, 23, 24 and 40mos post allo BMT. Long-term evaluation of these pts demonstrated fluctuations in persisting WT1-specific T-cell frequencies following DLI.
In one representative pt, a peak of 3.5% (72/ml) WT1-specific CD8 + T cells was detected in blood by staining with tetramer HLA-A*0201 RMF. This peak T-cell response post TCD HSCT and DLI coincided with disease regression. The pt has remained in complete remission for more than 3 years post transplant, with levels of WT1-specific CD8 + T cells ranging from 0.3-1.5% still persisting. Findings from concurrent molecular chimerism studies conducted on isolated T cells post TCD HSCT suggest that the WT1-specific T cells are of donor origin.
Immunohistochemical analyses of WT1 and CD138 co-staining in bone marrow specimens demonstrated consistent co-expression within malignant plasma cells. In 6 pts tested, WT1 expression in the bone marrow correlated with the extent of malignant plasma cell infiltration. In contrast, no WT1 expression was observed when disease was absent.
Our findings suggest an association between the emergence of WT1-specific T cells and graft-versus-myeloma effect in pts being treated for relapsed MM.
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UPFRONT TANDEM AUTOLOGOUS STEM CELL TRANSPLANT IS SUPERIOR THAN AUTOLOGOUS OR ALLOGENEIC STEM CELL TRANSPLANT AFTER FAILURE OF 1 ST AUTOLOGOUS TRANSPLANT IN PATIENTS WITH MULTI-PLE MYELOMA Bachier, C., Wong, A., Shaughnessy, P., LeMaistre, C.F. Texas Transplant Institute, San Antonio, TX Disease progression remains the main cause of treatment failure after autologous stem cell transplant (SCT) in patients with multiple myeloma (MM). It is unclear what is the best salvage therapy after failure of a 1 st autologous SCT in MM.
We performed a retrospective study comparing 2 nd autologous (auto-auto) versus 2 nd allogeneic (auto-allo) SCT in patients progressing or relapsing after their 1 st autologous SCT and compare their outcomes with patients receiving sequential planned double autologous (tandem) SCT as part of their upfront therapy for MM.
The data was collected from CIBMTR reports and medical records at Texas Transplant Institute from 2001 to 2010. Patient's characteristics and outcomes are described in table. Response to 1 st and 2 nd SCT was determined at 100 days post transplant and classified as good (stringent complete remission [sCR] , complete remission [CR], very good partial remission [VGPR]) or poor (partial remission [PR], stable disease [SD] or progressive disease [PD]). All patients in the auto-allo group received a reduced intensity regimen. The overall survival was calculated from the date of the 2 nd transplant to the known date of death in all groups. Patients in the auto-allo group (15.9 months) had a worse median survival than in the auto-auto group (39 months) with both of them having a worse survival compared to patients undergoing tandem transplants (64.3) (p value 5 0.003).
Forward stepwise Cox regression analysis was used to measure factors affecting overall survival. Factors used for analysis included age, cytogenetics (high risk 5 mutated p53, t(14;16), t(4;14), del 13), International Staging System (ISS) before 1 st and 2 nd SCT, use of maintenance therapy after 1 st SCT, days from diagnosis to 1 st SCT and days from 1 st to 2 nd SCT, CD34+ cells infused at 1 st and 2 nd SCT. Age and ISS of III at 2 nd transplant were identified as factors affecting survival in the auto-auto group (hazard ration of 1.081 and 5.700, respectively).
In conclusion, overall survival after salvage from 2 nd autologous stem cell transplant is longer than after a 2 nd allogeneic transplant. Upfront, planned tandem autologous stem cell transplant is superior to both salvage strategies. Larger, randomized trials are needed to confirm these results.
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